Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Clinical trial NCT07324824 · RECRUITING
Trial details
- NCT number
- NCT07324824
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-14
- Primary completion
- 2029-01-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.